GlassScriptPhysician profile
Ameesh Dara
NPI 1417367244
$7,116.40
in general payments reported to CMS, 2019-2025
24 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $637 · 2021: $401 · 2022: $376 · 2023: $4,276 · 2024: $617 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,375 · Food and Beverage: $1,613 · Travel and Lodging: $923 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,375.00 |
| Food and Beverage | $1,613.12 |
| Travel and Lodging | $922.98 |
| Education | $153.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,760.43 | 2022-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $775.12 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $550.99 | 2019-2024 | Jynarque |
| Mallinckrodt Enterprises LLC | $353.87 | 2019 | |
| Amgen INC. | $227.01 | 2019-2025 | Krystexxa, Tavneos |
| Nxstage Medical, INC. | $220.76 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $169.56 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $142.37 | 2020-2022 | |
| Boston Scientific Corporation | $133.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $127.32 | 2019-2024 | |
| Scpharmaceuticals INC. | $125.87 | 2023 | |
| Fresenius USA Marketing, INC. | $112.24 | 2024 | Liberty Select Cycler, Nxstage System One |
| Travere Therapeutics, INC. | $101.86 | 2023-2025 | |
| Novo Nordisk INC | $70.57 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $45.58 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.51 | 2023-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $26.43 | 2023 | Purified Cortrophin Gel |
| Rockwell Medical, INC. | $24.51 | 2020 | |
| Pfizer INC. | $23.17 | 2019 | |
| Recor Medical INC | $23.02 | 2025 | Paradise Ultrasound Renal Denervation System |
| Ardelyx, INC. | $18.58 | 2024 | Ibsrela |
| Vifor Pharma, INC. | $18.03 | 2023 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $16.45 | 2025 | Vafseo |
| Sanofi-Aventis U.S. LLC | $15.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ameesh Dara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.